By Ben Hirschler
LONDON (Reuters) Aug 02 –
A new AIDS drug could offer new hope to patients, but demand for it is so great its manufacturer warned on Friday it may not be able to supply the HIV fusion inhibitor T-20 to all those who need it.
Patient groups and AIDS activists have been clamoring for access to the new drug, which will be sold under the brand name Fuzeon, as an alternative treatment for tens of thousands of people who have become resistant to existing antiretroviral drugs.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!